1. Home
  2. FISI vs LYEL Comparison

FISI vs LYEL Comparison

Compare FISI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FISI

Financial Institutions Inc.

HOLD

Current Price

$34.94

Market Cap

643.4M

Sector

Finance

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$21.41

Market Cap

556.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FISI
LYEL
Founded
1817
2018
Country
United States
United States
Employees
631
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
643.4M
556.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
FISI
LYEL
Price
$34.94
$21.41
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$37.00
$30.60
AVG Volume (30 Days)
93.1K
76.7K
Earning Date
04-23-2026
05-13-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.22
$8,712.13
P/E Ratio
$9.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.41
$0.39
52 Week High
$35.67
$45.00

Technical Indicators

Market Signals
Indicator
FISI
LYEL
Relative Strength Index (RSI) 63.95 44.11
Support Level $26.91 $20.72
Resistance Level $35.49 $26.89
Average True Range (ATR) 0.80 1.62
MACD -0.01 -0.16
Stochastic Oscillator 67.50 7.84

Price Performance

Historical Comparison
FISI
LYEL

About FISI Financial Institutions Inc.

Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: